CA
NTLA icon

Cliff Asness’s Intellia Therapeutics NTLA Stock Holding History

Cliff Asness’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.34M Sell
492,954
-137,575
-22% -$1.93M ﹤0.01% 1684
2026
Q1 		$8.08M Buy
630,529
+316,834
+101% +$4.04M ﹤0.01% 1450
2025
Q4 		$2.82M Buy
313,695
+103,290
+49% +$1.42M ﹤0.01% 1924
2025
Q3 		$3.63M Buy
210,405
+73,865
+54% +$910K ﹤0.01% 1636
2025
Q2 		$1.28M Buy
136,540
+45,665
+50% +$375K ﹤0.01% 2052
2025
Q1 		$646K Buy
90,875
+55,118
+154% +$557K ﹤0.01% 2277
2024
Q4 		$417K Buy
+35,757
New +$558K ﹤0.01% 2341
2022
Q4 		– Sell
-5,048
Closed -$282K – 2252
2022
Q3 		$282K Sell
5,048
-3,230
-39% -$200K ﹤0.01% 1963
2022
Q2 		$428K Sell
8,278
-17,707
-68% -$899K ﹤0.01% 1735
2022
Q1 		$1.89M Sell
25,985
-14,715
-36% -$1.25M ﹤0.01% 1215
2021
Q4 		$4.81M Sell
40,700
-6,777
-14% -$849K 0.01% 839
2021
Q3 		$6.37M Buy
47,477
+11,901
+33% +$1.8M 0.01% 763
2021
Q2 		$5.76M Buy
35,576
+3,872
+12% +$302K 0.01% 815
2021
Q1 		$2.54M Buy
31,704
+11,414
+56% +$766K ﹤0.01% 1088
2020
Q4 		$1.1M Sell
20,290
-5,454
-21% -$198K ﹤0.01% 1455
2020
Q3 		$512K Buy
25,744
+5,169
+25% +$108K ﹤0.01% 1714
2020
Q2 		$432K Sell
20,575
-23,448
-53% -$398K ﹤0.01% 1793
2020
Q1 		$538K Sell
44,023
-15,614
-26% -$210K ﹤0.01% 1558
2019
Q4 		$875K Buy
59,637
+23,099
+63% +$321K ﹤0.01% 1557
2019
Q3 		$488K Buy
+36,538
New +$583K ﹤0.01% 1764
2018
Q4 		– Sell
-10,519
Closed -$301K – 2243
2018
Q3 		$301K Buy
10,519
+1,055
+11% +$30.7K ﹤0.01% 2106
2018
Q2 		$259K Sell
9,464
-5,327
-36% -$129K ﹤0.01% 2163
2018
Q1 		$312K Buy
+14,791
New +$364K ﹤0.01% 2040
2017
Q4 		– Sell
-22,640
Closed -$563K – 2259
2017
Q3 		$563K Buy
22,640
+10,137
+81% +$191K ﹤0.01% 1897
2017
Q2 		$200K Buy
+12,503
New +$175K ﹤0.01% 2129

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Cliff Asness's NTLA Position: Q2 2026 in Review

Cliff Asness reduced its Intellia Therapeutics (NTLA) stake by 22% in Q2 2026, selling an estimated $1.93M and leaving 492,954 shares worth $8.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1684.

Cliff Asness first reported a position in NTLA in Q2 2017 and has held it in 25 quarters since. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Cliff Asness held 492,954 shares of Intellia Therapeutics worth $8.34M as of Q2 2026.
  • Cliff Asness sold 137,575 Intellia Therapeutics shares in Q2 2026, an estimated $1.93M.
  • Intellia Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #1684 holding.
  • Cliff Asness first reported a position in Intellia Therapeutics in Q2 2017 and has held it in 25 quarters since.
  • 326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.